In adults with obesity receiving intensive behavioral therapy, complete adherence to liraglutide 3.0 mg predicted an additional weight loss relative to non-adherence to the medication.
In plain wordsIn adults with obesity, people who fully took liraglutide 3.0 mg lost more weight than people who did not take it as directed.
- Peptide
- Liraglutide
- Outcome
- DecreaseWeight change at week 56 with complete adherence to liraglutide
- Study
n = 142
- Comparator
- Non-adherence to liraglutide
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- 3.0 mg · 56 weeksAs given in this study (human).
Measurements
- Additional weight change
- −6.5%
- complete adherence to liraglutide versus non-adherence
Source sentences
Complete adherence to liraglutide predicted an additional weight loss of -6.5% (95% CI -10.2 to -2.9; p = 0.0005) relative to individuals who did not adhere to the medication regimen
1 context sentence(design, population, supporting numbers)
SCALE IBT was a double-blinded, multicenter, randomized controlled trial comparing 56-week weight losses in individuals with obesity who received liraglutide 3.0 mg (n = 142) or placebo (n = 140), as an adjunct to IBT.